Top

Investigational New Drugs

Published in:

01-08-2001

Phase II Trial of GM-CSF in Advanced Prostate Cancer

Authors: Robert Dreicer, William A. See, Eric A. Klein

Published in: Investigational New Drugs | Issue 3/2001

Title: Phase II Trial of GM-CSF in Advanced Prostate Cancer
Authors: Robert Dreicer
William A. See
Eric A. Klein
Publication date: 01-08-2001
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 3/2001
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1010637105066

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/2001

Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial

In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells

A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

Instructions for Authors

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer